Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24407575 | 0.84 | FLT1 (0.43) | MAP2K1KDRFLT1P2RX7MAP2K2 | |
| SCHEMBL24407548 | 0.84 | MAP2K1 (0.40) | MAP2K1KDRFLT1P2RX7MAP2K2 | |
| SCHEMBL26047568 | 0.84 | MAP2K1 (0.46) | MAP2K1KDRFLT1P2RX7MAP2K2 | |
| SCHEMBL24407530 | 0.84 | FLT1 (0.42) | MAP2K1KDRFLT1P2RX7MAP2K2 | |
| SCHEMBL24407573 | 0.82 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL26047554 | 0.82 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL24407522 | 0.82 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL24407549 | 0.81 | MAP2K1 (0.44) | MAP2K1KDRFLT1P2RX7MAP2K2 | |
| SCHEMBL24407571 | 0.78 | ALDH1A1 (0.38) | MAP2K1KDRFLT1 | |
| SCHEMBL26048477 | 0.78 | ALDH1A1 (0.38) | MAP2K1KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |